Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. (NYSE: DVA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its kidney care operations, capital structure and governance. This page aggregates those SEC filings and pairs them with AI-powered tools to help readers understand the implications for the company’s dialysis and integrated kidney care business.
For DaVita, current reports on Form 8-K are particularly informative. Recent 8-K filings describe quarterly financial results, including consolidated revenues, operating income, cash flow and key U.S. dialysis metrics, as well as board actions such as increases to the company’s share repurchase authorization. Other 8-Ks outline material definitive agreements, including amendments to DaVita’s senior secured credit facilities that establish new term loan and revolving credit arrangements and explain how proceeds may be used for refinancing, working capital and general corporate purposes.
Investors following DVA can also use SEC filings to track topics such as share repurchases, debt issuance and integrated kidney care strategy. Disclosures around authorization levels for repurchase programs, limitations under credit agreements and the company’s approach to capital allocation appear in these documents. Filings related to financial results provide context on DaVita’s role as a comprehensive kidney care provider, its global network of outpatient dialysis centers and its participation in value-based care models.
On this page, AI-generated summaries highlight the main points of each filing, explain technical language and draw attention to items that may matter to shareholders, such as changes in credit facilities, repurchase authorizations or reported operating performance. Users can quickly locate DaVita’s quarterly and annual reports when available, review Form 8-K disclosures and examine any insider-related filings, while relying on AI assistance to interpret how these regulatory documents relate to the company’s kidney care operations and financial profile.
DaVita Inc. (DVA) insider filing reports a sale of 401,514 shares of common stock on 10/27/2025 at a price of $135.3558 per share. Following the transaction, the reporting persons collectively beneficially owned 31,759,065 shares, held indirectly.
Footnotes state that 15,126,977 shares are owned by Government Employees Insurance Company (a Berkshire Hathaway subsidiary). An additional 16,632,088 shares are held by pension plans: BNSF Master Retirement Trust 6,100,000 and Berkshire Hathaway Inc. Consolidated Pension Plan 10,532,088. The filing is signed “/s/ Warren E. Buffett” on behalf of the reporting persons.
DaVita Inc. filed its Q3 2025 10‑Q, reporting higher revenue and continued buybacks. Total revenues were $3,420,227 thousand, up from $3,263,590 thousand a year ago. Operating income was $505,767 thousand. Net income attributable to DaVita Inc. was $150,332 thousand, with diluted EPS of $2.04.
For the first nine months, revenues reached $10,023,282 thousand and net cash provided by operating activities was $1,345,774 thousand. The company repurchased 3,274 thousand shares in Q3 for $465,141 thousand and 10,001 thousand shares year‑to‑date for $1,461,387 thousand. As of October 28, 2025, approximately 70.6 million shares were outstanding.
DaVita issued $1,000,000 of 6.75% senior notes due 2033 and refinanced into a Term Loan B‑2 of $1,873,254; long‑term debt stood at $10,183,863 thousand. The weighted average effective interest rate on all debt was 5.70% in Q3. The company acquired Fresenius Medical Care’s Brazil dialysis operations for $94,282 thousand, contributing to total 2025 acquisition consideration of $108,015 thousand.
DaVita Inc. furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information is being furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth. Additional materials include Exhibit 104.0 for the cover page Inline XBRL tags.
David Paul Maughan, Chief Operating Officer of DaVita Inc. (DVA), reported a transaction on 09/22/2025. The filing shows 7,501 shares of common stock were disposed of at a price of $130.16 per share through withholding to satisfy tax obligations. Those withheld shares represent 50% of 17,145 restricted stock units that vested for the reporting person from a grant dated September 22, 2022. After the withholding, the reporting person beneficially owns 122,266 shares. The form was signed by an attorney-in-fact on behalf of the reporting person.
DaVita Inc. reported that its board of directors has increased the authorization under its existing share repurchase program by an additional
The company is not obligated to buy back any shares and may conduct repurchases in the open market or through privately negotiated transactions, including under its share repurchase agreement dated April 30, 2024 with Berkshire Hathaway Inc., as well as through accelerated share repurchases, derivatives, tender offers or Rule 10b5-1 plans. The timing and size of any repurchases will depend on market conditions, legal and contractual limits, and other factors, and DaVita can modify, suspend or discontinue the program at any time.
DaVita Inc. director Adam H. Schechter reported a non-derivative acquisition of company stock on 08/15/2025. The filing shows 369 shares were acquired with a reported price of $0, leaving the reporting person with 4,699 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 08/19/2025. No derivative transactions or additional remarks are reported in the filing.
Phyllis R. Yale, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the reported transaction she beneficially owned 13,570 shares. The Form 4 was filed as an individual filing for one reporting person and was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Barbara J. Desoer, through an attorney-in-fact, reported acquiring 369 shares of DaVita common stock on 08/15/2025 at no cash price indicated on the form and holds 369 shares directly following the transaction. The filing shows she also has indirect beneficial ownership of 12,659 shares through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The Form 4 was signed by Stephanie N. Berberich as attorney-in-fact on 08/19/2025.
Insider transaction summary: This Form 4 shows that Jason M. Hollar, a director of DaVita Inc. (DVA), acquired 369 shares of DaVita common stock on 08/15/2025. The reported acquisition is coded as A and lists a price of $0, indicating the shares were received without cash payment (e.g., a grant or similar issuance). After the transaction, Mr. Hollar beneficially owned 5,612 shares. The filing was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Gregory J. Moore acquired 369 shares of DaVita common stock on 08/15/2025 at no reported cash price (Code V). After the transaction he beneficially owned 6,820 shares, held directly. The Form 4 discloses this routine insider purchase; no derivative transactions or additional disclosures are reported in the filing.